Boston Trust Walden Corp trimmed its position in shares of Solventum Co. (NYSE:SOLV – Free Report) by 9.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,636 shares of the company’s stock after selling 383 shares during the quarter. Boston Trust Walden Corp’s holdings in Solventum were worth $254,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in SOLV. Fifth Lane Capital LP acquired a new position in shares of Solventum during the first quarter worth about $826,000. Boit C F David acquired a new position in shares of Solventum during the first quarter worth about $152,000. Mitsubishi UFJ Trust & Banking Corp acquired a new position in shares of Solventum during the first quarter worth about $5,747,000. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new position in shares of Solventum during the first quarter worth about $209,000. Finally, LRI Investments LLC acquired a new position in shares of Solventum during the first quarter worth about $43,000.
Solventum Trading Down 0.0 %
Shares of NYSE SOLV opened at $73.19 on Monday. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $96.05. The company has a quick ratio of 0.96, a current ratio of 1.31 and a debt-to-equity ratio of 2.90. The firm’s 50-day moving average is $67.58 and its two-hundred day moving average is $61.26.
Wall Street Analyst Weigh In
A number of research firms recently commented on SOLV. Morgan Stanley decreased their price objective on shares of Solventum from $70.00 to $55.00 and set an “equal weight” rating on the stock in a report on Monday, July 15th. Piper Sandler began coverage on shares of Solventum in a report on Monday, October 7th. They set a “neutral” rating and a $71.00 price objective on the stock. BTIG Research began coverage on shares of Solventum in a report on Thursday, September 5th. They set a “neutral” rating on the stock. The Goldman Sachs Group boosted their price objective on shares of Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a report on Monday, August 12th. Finally, Wells Fargo & Company decreased their price objective on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a report on Friday, August 9th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $64.33.
Read Our Latest Report on SOLV
Solventum Company Profile
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Recommended Stories
- Five stocks we like better than Solventum
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- What is the FTSE 100 index?
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Stock Average Calculator
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.